We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Celgene Continues Active January With $9B Juno Acquisition

Law360, New York (January 22, 2018, 8:49 AM EST) -- Celgene has agreed to buy rival biotechnology business Juno Therapeutics for around $9 billion, the companies said Monday, marking the second multibillion-dollar acquisition made by Celgene this month.

Under the terms...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.